X

FIERCELY FOCUSED
ON SCIENCE

OUR PIPELINE

REGIMEN DISEASE PRECLINICAL PHASE 1 PHASE 2 PHASE 3 REGISTRATION STATUS LEARN MORE
Ublituximab IV:
glycoengineered anti-CD20 mAb
Relapsing MS
ULTIMATE I & II - APPROVED 12/28/22
Ublituximab IV:
glycoengineered anti-CD20 mAb
Relapsing MS
ENHANCE >>
Ublituximab Subcutaneous:
glycoengineered anti-CD20 mAb
Relapsing MS
>>
Azer-Cel:
CD19 directed allogeneic CAR-T
B-cell disorders
>>

The safety and efficacy of our investigational compounds and investigational uses of approved products have not been established. These products and uses have not been approved by the US Food and Drug Administration or other health authorities.

Scroll to Top